In a research report sent to investors today, Roth Capital analyst Ed Arce reiterated a Buy rating on Xoma (NASDAQ:XOMA) with a $9 …
Roth Capital analyst Ed Arce reiterated a Buy rating on Acura (NASDAQ:ACUR) with a price target of $1.50, which represents a potential upside …
In a research report issued Friday, Roth Capital analyst Ed Arce maintained a Buy rating on BioCryst Pharmaceuticals (NASDAQ:BCRX) with a $20 price …
In a report sent to investors today, analyst Ed Arce of Roth Capital maintained a Buy rating on Sucampo (NASDAQ:SCMP) and raised his price target to $18 (from …
In a research report issued today, Roth Capital analyst Ed Arce reiterated a Neutral rating on Acelrx Pharmaceuticals (NASDAQ:ACRX) with a price target …
In a research report issued today, Roth Capital analyst Ed Arce downgraded shares of Durata Therapeutics (NASDAQ:DRTX) from Buy to Neutral, while maintaining his $23 …
In a research report released Wednesday, Roth Capital analyst Ed Arce Affirmed a Buy rating on Sucampo (NASDAQ:SCMP) with a $9 price target, as the company extended its …
In a research report released to investors today, analyst Ed Arce of Roth Capital reiterated a Buy rating on Sucampo (NASDAQ:SCMP) with a $9.00 price …
In a research report sent to investors today, Roth Capital analyst Ed Arce assumed coverage on Xoma (NASDAQ:XOMA) shares with a Buy rating and a $9.00 price …
In a research report issued yesterday, Roth Capital analyst Ed Arce maintained a Buy rating on Durata Therapeutics (NASDAQ:DRTX) and reduced his price …
